Colorectal Cancer

The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

The STELLAR-303 trial met its OS end point with the zanzalintinib regimen in the ITT population but failed to show the same benefit in the NLM subgroup.

The FDA has accepted for review an sBLA for adjuvant atezolizumab plus chemotherapy in stage III dMMR/MSI-H colon cancer.

Need a refresh on the current regulatory landscape for GI oncology? We have it covered. Here's everything that moved the needle across GI malignancies this month.

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

CIRCULATE provides the first prospective randomized evidence in support of a ctDNA-guided treatment escalation strategy in pMMR/MSS stage II colon cancer.

Encorafenib plus cetuximab and FOLFIRI improved PFS vs chemotherapy alone in first-line BRAF V600E–mutant metastatic colorectal cancer.

The European Medicines Agency’s CHMP has issued a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in first-line BRAF V600E–mutant mCRC.

Marwan G. Fakih, MD, outlines situations when ctDNA and tissue NGS agree, when they diverge, and scenarios that should prompt repeat liquid biopsy testing.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

The FDA has granted fast track designation to suplexa in MSI-H CRC.

Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.

Pelareorep plus bevacizumab and FOLFIRI showed a 33% response rate and 19.5-month median response duration in RAS-mutant MSS CRC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

Ozekibart plus FOLFIRI produced ORRs that exceed historical benchmarks for standard later-line CRC regimens.

Translational analyses from NEOPRISM-CRC also link ctDNA clearance/kinetics and TCR clonality with pCRs, supporting biomarker-guided treatment selection.